Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.26 Analyst target: $6.92 Upside: 449.21%
Neurotrope, Inc., a biopharmaceutical company, is focused on developing a product platform for the treatment of Alzheimer's disease. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.